Literature DB >> 2556698

A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses.

P Roux1, P Jeanteur, M Piechaczyk.   

Abstract

A technique for delivering genes carried by recombinant retroviruses into specific cell types could have numerous applications in oncology, developmental biology, and gene therapy. As a first step toward this remote goal we designed a procedure allowing in vitro cell targeting by retroviruses. Biotinylated antibodies against the viral envelope protein on one side, and against specific cell membrane markers on the other side, were bridged by streptavidin and used to link the virus to the host. The method was successfully used to infect human cells with ecotropic murine retroviruses by means of major histocompatibility complex class I and class II antigens and appears easily adaptable to other cell membrane markers. Moreover, the sequential protocol we designed, although allowing infection of human cells, requires less stringent safety constraints than would handling of amphotropic virus stocks.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556698      PMCID: PMC298437          DOI: 10.1073/pnas.86.23.9079

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  Interferon and major histocompatibility complex genes: a model to analyse eukaryotic gene regulation?

Authors:  F M Rosa; M M Cochet; M Fellous
Journal:  Interferon       Date:  1986

2.  Functional association of class II antigens with cell surface binding of Epstein-Barr virus.

Authors:  P S Reisert; R C Spiro; P L Townsend; S A Stanford; T Sairenji; R E Humphreys
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

3.  Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene.

Authors:  A D Miller; M F Law; I M Verma
Journal:  Mol Cell Biol       Date:  1985-03       Impact factor: 4.272

4.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

5.  Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells.

Authors:  R G Hawley; L Covarrubias; T Hawley; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

6.  Recombinant retroviruses encoding simian virus 40 large T antigen and polyomavirus large and middle T antigens.

Authors:  P S Jat; C L Cepko; R C Mulligan; P A Sharp
Journal:  Mol Cell Biol       Date:  1986-04       Impact factor: 4.272

7.  Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses.

Authors:  B Chesebro; K Wehrly
Journal:  Virology       Date:  1985-02       Impact factor: 3.616

8.  Amphotropic retrovirus vector system for human cell gene transfer.

Authors:  J Sorge; D Wright; V D Erdman; A E Cutting
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

9.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells.

Authors:  S F Yu; T von Rüden; P W Kantoff; C Garber; M Seiberg; U Rüther; W F Anderson; E F Wagner; E Gilboa
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

10.  Cell surface receptors for murine leukemia viruses: two assays and their implications.

Authors:  B L Handelin; D Kabat
Journal:  Virology       Date:  1985-01-15       Impact factor: 3.616

View more
  36 in total

1.  Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.

Authors:  A L Boerger; S Snitkovsky; J A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Identification of the block in targeted retroviral-mediated gene transfer.

Authors:  Y Zhao; L Zhu; S Lee; L Li; E Chang; N W Soong; D Douer; W F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope.

Authors:  Timothy J Gollan; Michael R Green
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Antibody-directed targeting of retroviral vectors via cell surface antigens.

Authors:  K Morizono; G Bristol; Y M Xie ; S K Kung; I S Chen
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Targeting lentiviral vectors to specific cell types in vivo.

Authors:  Lili Yang; Leslie Bailey; David Baltimore; Pin Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

6.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

Review 7.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

Review 8.  Retroviral vectors. From laboratory tools to molecular medicine.

Authors:  R G Vile; A Tuszynski; S Castleden
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

Review 9.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

10.  Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.

Authors:  S Valsesia-Wittmann; A Drynda; G Deléage; M Aumailley; J M Heard; O Danos; G Verdier; F L Cosset
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.